The trend is apparent in the FDA's approval ofexpanded indications for biotech drugs.
FDA扩大生物药品的适应症的决定中体现了明显的趋势。
Biosimilars are generic impersonations (although not identical copies) of biotech drugs.
生物仿制制药是对生物技术制药进行的非专利仿制(尽管不是完全一致的复制)。
European drug regulators recently created a pathway for generic ersions of biotech drugs to come to market.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
European drug regulators recently created a pathway for generic versions of biotech drugs to come to market.
欧洲药物管理部门近来开创了一条允许非专利生物技术药物进入市场的通道。
Now they are investing in more personalised medicine: biotech drugs that treat small groups of patients more effectively.
现在则投向更个体化的药物，即更有效治疗小部分病患的生物技术药物。
Last year biotech drugs accounted for 70% of the increase in pharmaceutical costs in America, according to Medco, a drug-plan manager.
据药品计划管理公司Medco（中文名：美可）称，去年生物技术药品占美国药品费用增长额的70%。
Now that there are several targeted biotech drugs on the market, researchers are starting to test whether two targeted drugs are better than one.
既然市场上有很多靶向生物技术药物，那么研究者正开始试验两个靶向药物是否会比一个更好些。
With few new treatments emerging from the drugdevelopment pipeline, drugmakers are pouring money intofinding new uses for specialized biotech drugs that may beeffective against multiple diseases.
新药研发中的出现的新治疗手段也少之又少，制药商转而把钱花在寻找能够治疗多种疾病的特殊生物药品上。
Biotech drugs provide something of a hedge against this coming calamity, for two reasons. First, they are much harder to copy, so generic equivalents (called "biosimilars") will be slow in coming.
而生物技术制药可以提供抵抗这一灾难的利器，其中原因有二：第一，这些技术非常难摹仿，所以被称为“生物相似药”的普通替代品很难进入市场；
Pfizer last week announced a deal with Canadian biotech Tekmira Pharmaceuticals Corp for this type of delivery vehicle for its RNAi drugs, joining Roche and Alnylam.
辉瑞公司上周宣布，已与罗氏和Alnylam一道，就这种形式的RNAi药物运输工具与加拿大生物技术Tekmira制药公司达成一笔交易。
The results are expected in 2013. And though Barzilai is not affiliated with that project, he is working on his own longevity drugs through a biotech start-up he established with a colleague.
结果将在2013年发布，尽管Barzilai并不在该项目中，他正在通过和同事合作研发的生物技术开发自己的长寿药。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
By and large, the inventions and discoveries worth patenting are those in the pharmaceutical and biotech fields, where the pay-off for blockbuster drugs can amount to billions of dollars a year.
总的来说，值得授予专利的发明和发现是在制药和生物技术领域，在该领域每年都能推出价值可达数十亿美元，影响重大的新药。
We hand that list over to the universities, the pharmaceuticals, the biotech companies to start developing new drugs because those mutated genes and their proteins are targets for new therapeutics.
我们把该列表交给了大学，制药厂，生物科技公司，开始开发新的药物，因为这些突变基因及其蛋白质是新的治疗靶点。
The biotech industry says the complexity and unpredictability of biologically derived drugs mean generics should be subject to extensive tests in humans before being approved.
生物技术企业声称生物技术药物的复杂性和不可预知性意味着非专利生物技术药物在获得许可之前应经过广泛的人体测试实验。
A small Australian biotech company has patients that it claims cover key methods of diagnosing how susceptible an individual is to particular diseases and tailoring drugs to their needs.
一家拥有多项专利技术的小型澳洲生化公司声称其掌握了对人们的个体特质进行疾病预诊并定制药物的方法。
The company said half of its new drugs entering trials this year will be biologics and it plans to bring a new biotech product to market every year starting in 2011.
今年，礼来公司进入临床试验的药物一半是生物技术药物。公司计划自2011年起，每年有一个生物技术药物上市。
It would mean relying entirely on partnerships with biotech companies when the cost of licensing-in drugs is rising.
因为这就意味着，一旦特许药的成本上升，制药公司就只能完全依赖与生物技术公司的合作关系了。
It would mean relying entirely on partnerships with biotech companies when the cost of licensing-in drugs is rising.
因为这就意味着，一旦特许药的成本上升，制药公司就只能完全依赖与生物技术公司的合作关系了。
应用推荐